Chlamydia pneumoniae and cardiovascular disease

Medical Journal of Australia

Volumn 177, Issue 10, 2002, Pages 558-562

  Larsen, Mikkel M ^a   Moern, Birgitte ^a   Fuller, Andrew ^b   Andersen, Paul L ^a   Ostergaard, Lars J ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ATORVASTATIN; AZITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; MACROLIDE; METRONIDAZOLE; OMEPRAZOLE; PENICILLIN G; PLACEBO; PRAVASTATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ATHEROSCLEROTIC PLAQUE; BACTERIUM DETECTION; CARDIOVASCULAR DISEASE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CORONARY RISK; DISEASE ASSOCIATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; HUMAN; NONHUMAN; OUTCOMES RESEARCH; PATHOLOGY; PROSPECTIVE STUDY; REVIEW; SEROLOGY; STANDARD; VASCULAR DISEASE;

EID: 0037132072     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2002.tb04953.x     Document Type: Review

References (40)

1. Gimenez-Sanchez F, Butler JC, Jernigan DB, et al. Treating cardiovascular disease with antimicrobial agents: A survey of knowledge, attitudes, and practices among physicians in the United States. Clin Infect Dis 2001; 33: 171-176.
2. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-986.
3. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet 1997; 350: 430-436.
4. Danesh J, Whincup P, Lewington S, et al. Chlamydia pneumoniae IgA titres and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2002; 23: 371-375.
5. Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis. BMJ 2000; 321: 208-213.
6. Gupta S, Camm AJ. Chlamydia pneumoniae and coronary heart disease. BMJ 1997; 314: 1778-1779.
7. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: Recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33: 492-503.
8. Cook PJ, Lip GY, Davies P, et al. Chlamydia pneumoniae antibodies in severe essential hypertension. Hypertension 1998; 31: 589-594.
9. Leinonen M, Saikku P. Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis. Am Heart J 1999; 138: S504-S506.
10. Murray LJ, O'Reilly DP, Ong GM, et al. Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile. Heart 1999; 81: 239-244.
11. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-241.
12. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 2000; 181 Suppl 3: S402-S410.
13. Gaydos CA. Growth in vascular cells and cytokine production by Chlamydia pneumoniae. J Infect Dis 2000; 181 Suppl 3: S473-S478.
14. Maass M, Bartels C, Engel PM, et al. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 31: 827-832.
15. Kuo C, Campbell LA. Detection of Chlamydia pneumoniae in arterial tissues. J Infect Dis 2000; 181 Suppl 3: S432-S436.
16. Apfalter P, Blasi F, Boman J, et al. Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens. J Clin Microbiol 2001; 39: 519-524.
17. Mosorin M, Surcel HM, Laurila A, et al. Detection of Chlamydia pneumoniae-reactive T lymphocytes in human atherosclerotic plaques of carotid artery. Arterioscler Thromb Vasc Biol 2000; 20: 1061-1067.
18. Curry AJ, Portig I, Goodall JC, et al. T lymphocyte lines isolated from atheromatous plaque contain cells capable of responding to Chlamydia antigens. Clin Exp Immunol 2000; 121: 261-269.
19. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998; 177: 725-729.
20. Mayr M, Kiechl S, Willeit J, et al. Infections, immunity, and atherosclerosis: Associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000; 102: 833-839.
21. Moazed TC, Campbell LA, Rosenfeld ME, et al. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Infect Dis 1999; 180: 238-241.
22. Fong IW, Chiu B, Viira E, et al. De novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect Immun 1999; 67: 6048-6055.
23. Campbell LA, Rosenfeld M, Kuo CC. The role of Chlamydia pneumoniae in atherosclerosis - Recent evidence from animal models. Trends Microbiol 2000; 8: 255-257.
24. Meier CR. Antibiotics in the prevention and treatment of coronary heart disease. J Infect Dis 2000; 181 Suppl 3: S558-S562.
25. Jackson LA, Smith NL, Heckbert SR, et al. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg Infect Dis 1999; 5: 281-284.
26. Meier CR, Derby LE, Jick SS, et al. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999; 281: 427-431.
27. Ostergaard L, Sorensen HT, Lindholt J, et al. Risk of hospitalization for cardiovascular disease after use of macrolides and penicillins: A comparative prospective cohort study. J Infect Dis 2001; 183: 1625-1630.
28. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-407.
29. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary clinical results of the ACADEMIC study. Circulation 2000; 102: 1755-1760.
30. Gurfinkel E, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999; 20: 121-127.
31. Neumann F, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): A randomised, double-blind, placebo-controlled trial. Lancet 2001; 357: 2085-2089.
32. Vammen S, Lindholt JS, Ostergaard L, et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 2001; 88: 1066-1072.
33. Jackson LA. Description and status of the azithromycin and coronary events study (ACES). J Infect Dis 2000; 181 Suppl 3: S579-S581.
34. Coletta A, Thackray S, Nikitin N, Cleland JG. Clinical trials update: Highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL. Eur J Heart Fail 2002; 4: 381-388.
35. Hansen S, Als-Nielsen B, Damgaard M, et al. Intervention with clarithromycin in patients with stable coronary heart disease. Heart Drug 2001; 1: 14-19.
36. CROAATS Study Group. Double-blind placebo-controlled multicenter study of the effects of azithromycin in Chlamydia pneumoniae positive post-myocardial infarction patients (CROAATS) - Study announcement. Available at Accessed Aug 2002.
37. Smith D. MARBLE (Might Azithromycin Reduce Bypass List Events). Elsevier Medical Journals, Cardio Source. Available at Accessed Aug 2002.
38. Cannon CP, McCabe CH, Belder R, et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002; 89: 860-861.
39. Stone AFM, Mendall MA, Kaski J, et al. The South Thames trial of antibiotics in myocardial infarction and unstable angina (STAMINA) trial. Presented at the European Society of Cardiology XXIII Congress, Sep 1-5 2001. Available at Accessed Aug 2002.
40. Pfizer Inc. Pfizer completes first large-scale study of antibiotic potential in reducing cardiovascular events [press release]. Mar 18 2002. Available at Accessed Aug 2002.